Shire makes $30bn hostile offer for Baxalta; finalized at $32bn
Shire PLC took an unsolicited offer to acquire newly public Baxalta Inc. directly to Baxalta's board: Shire would issue 0.1687 ADRs for each Baxalta share, valuing the deal at $30bn or approximately $44.06 per share (a 39% premium). Upon closing, Baxalta would own 37% of the combined company, but within two years Shire plans to repurchase up to 13% of the combined shares via a share buyback.
- Gene Therapy, Cell Therapy
- Large Molecule
- Full Acquisition
- Includes Contract
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.